$66.03 Million in Sales Expected for Arcus Biosciences Inc (NYSE:RCUS) This Quarter

Share on StockTwits

Wall Street analysts predict that Arcus Biosciences Inc (NYSE:RCUS) will announce $66.03 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Arcus Biosciences’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $182.70 million. Arcus Biosciences posted sales of $1.75 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3,673.1%. The company is expected to issue its next quarterly earnings results on Tuesday, November 3rd.

According to Zacks, analysts expect that Arcus Biosciences will report full-year sales of $75.48 million for the current financial year, with estimates ranging from $6.00 million to $188.20 million. For the next financial year, analysts forecast that the company will post sales of $282.70 million, with estimates ranging from $57.50 million to $507.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Arcus Biosciences.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.39). Arcus Biosciences had a negative net margin of 745.18% and a negative return on equity of 49.11%. The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $1.50 million.

RCUS has been the topic of a number of recent research reports. Zacks Investment Research cut shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a report on Tuesday, May 19th. SunTrust Banks increased their price target on shares of Arcus Biosciences from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. SVB Leerink increased their price objective on shares of Arcus Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Finally, Citigroup increased their price objective on shares of Arcus Biosciences from $15.00 to $41.00 in a research report on Tuesday, June 2nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Arcus Biosciences currently has an average rating of “Buy” and an average price target of $37.67.

Arcus Biosciences stock traded up $0.08 during mid-day trading on Thursday, reaching $21.04. The company’s stock had a trading volume of 550,800 shares, compared to its average volume of 537,174. The company has a market capitalization of $1.37 billion, a P/E ratio of -8.59 and a beta of 1.17. Arcus Biosciences has a 12-month low of $7.19 and a 12-month high of $37.41. The firm’s fifty day moving average price is $22.83 and its two-hundred day moving average price is $22.98.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its position in Arcus Biosciences by 3,297.7% in the second quarter. FMR LLC now owns 2,705,575 shares of the company’s stock worth $66,936,000 after acquiring an additional 2,625,945 shares during the period. Vanguard Group Inc. raised its position in shares of Arcus Biosciences by 43.8% during the 2nd quarter. Vanguard Group Inc. now owns 2,193,120 shares of the company’s stock valued at $54,257,000 after purchasing an additional 668,026 shares during the period. BVF Inc. IL raised its position in shares of Arcus Biosciences by 4,780.8% during the 2nd quarter. BVF Inc. IL now owns 1,882,722 shares of the company’s stock valued at $46,579,000 after purchasing an additional 1,844,148 shares during the period. Victory Capital Management Inc. raised its position in shares of Arcus Biosciences by 18,319.4% during the 2nd quarter. Victory Capital Management Inc. now owns 892,604 shares of the company’s stock valued at $22,083,000 after purchasing an additional 887,758 shares during the period. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Arcus Biosciences during the 2nd quarter valued at $21,892,000. Institutional investors and hedge funds own 56.68% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Article: Net Income

Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply